Skip to main content

Advertisement

Table 3 Univariate analysis of therapeutic regimens used in patients with carbapenem-resistant infections on infection-related deaths

From: A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome

Treatment Total (n = 127) N (%) Survivors (n = 83) N (%) Deaths (n = 44) N (%) RR (95 % CI) P
Less than12 h onset 39 (30.7) 20 (24.1) 19 (43.2) 1.39 (1.00–1.94) 0.02
12 h onset and sensitive 31 (24.4) 14 (16.9) 17 (38.6) 1.59 (1.05–2.39) 0.006
Less than 24 h onset 53 (41.7) 30 (36.1) 23 (52.3) 1.26 (0.96–1.66) 0.059
Monotherapy 29 (22.8) 23 (27.7) 6 (13.6) 0.77 (0.60–0.98) 0.054
Combined therapy 98 (77.2) 60 (72.3) 38 (86.4) 1.29 (1.01–1.65) 0.054
 2 drugs 22 (17.3) 16 (19.3) 6 (13.6) 0.87 (0.65–1.17) 0.29
 3 drugs 53 (41.7) 31 (37.3) 22 (50.0) 1.20 (0.91–1.57) 0.11
 4 drugs 23 (18.1) 13 (15.6) 10 (22.7) 1.19 (0.81–1.74) 0.22
Colistin 107 (8.2) 67 (80.7) 40 (90.9) 1.27 (0.98–1.66) 0.10
Loading dose of colistin 74 (69.2) 43 (64.2) 31 (77.5) 1.25 (0.94–1.66) 0.10
Tigecycline 69 (54.3) 43 (51.8) 26 (59.0) 1.10 (0.86–1.42) 0.27
Double dose of tigecyclin 46 (66.8) 29 (67.5) 17 (65.4) 0.96 (0.65–1.43) 0.53
Carbapenem 69 (54.3) 42 (50.6) 27 (61.4) 1.16 (0.90–1.49) 0.16
Aminoglycoside 82 (64.6) 51 (61.4) 31 (70.4) 1.14 (0.88–1.47) 0.20
Use of more two or more drugs with in vitro activity on isolates 71 (55.9) 45 (54.2) 26 (59.0) 1.07 (0.83–1.37) 0.36
  1. RR relative risk, CI confidence interval